Brain Health

Eisai plans to file for traditional approval in the United States by March 31, 2023.

Ozanimod is an oral, sphinogosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5.

Tacrine was originally brought to the market in 1993 as an acetylcholinesterase inhibitor to fight the symptoms of Alzheimer disease.

Deutetrabenazine is the only VMAT2 inhibitor approved by the FDA for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntington disease.

Although the treatment of motor symptoms is the primary focus of care for Parkinson disease, helping these patients with sleep disorders is vital because of the impact on quality of life.

The new data came from Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled (SHARP) study.

New research about the risks of dementia in patients with non-affective psychotic disorders could help shape new life course models for prevention.

New research suggests that psychedelics, and specifically ketamine, can increase neuroplasticity to help a patient with an eating disorder get “unstuck,” and help treat the disorder better than psychotherapy alone.

The history of targeting neuroinflammation is a good example of the challenges to finding a treatment for Alzheimer disease.

In a study of 2262 individuals, investigators also found that cocoa extract had no effect on cognition.

Changing one’s diet could change brain health and study results suggest the Mediterranean diet could positively support cognitive function.

Research suggests cannabis can improve quality of life for patients who suffer from pain and neurological disorders.

Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.

Very short sleep among adolescents linked to a more than 70% increased risk of obesity/overweight in children, compared to those who get optimal 8 hours.

A new study suggests that work and private life mental stressors are disrupting sleep in older employees, potentially wreaking havoc on health.

Investigators used the FDA-approved concussions test i-STAT TBI Plasma and the company’s core laboratory Architect instrument.

The meta-analysis reviews 38 available studies on the effects of cognitive, physical, and social activities on brain function.

Children may have suboptimal long-term brain development if their mother smokes tobacco consistently during pregnancy.

Pharmacists can play an important role in helping ensure compliance with prescribed medications, which can help seniors maintain their health and quality of life while aging at home.

A recent study revealed that social activities like gardening or getting a college degree could improve cognition in older age, which could possibly prevent Alzheimer disease.

Older individuals who were exposed to any amount of light while sleeping were significantly more likely to be obese, have high blood pressure, and have diabetes.

For every 10% increase in daily intake of ultra-processed foods, people had a 25% higher risk of dementia, though the association is not proven to be causal.

The FDA has approved daridorexant (Quviviq; Idorsia Pharmaceuticals, US Inc) to treat adults with insomnia.

Lumryz (FT218) treats cataplexy and excessive daytime sleepiness caused by narcolepsy.

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Instant Sleep is intended to aid with falling asleep faster and staying asleep longer.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.

Surprising turn of events is a strong message to the pharmaceutical industry about the acceptable developmental pathway for this drug class.

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.